Sonja Willems – Managing Director, Janssen Benelux
Janssen in Belgium was founded in 1953 by Dr Paul Janssen, with only one thing in mind: saving people’s lives through the development of better medicines. In 1961, the company…
Address: Essenscia Diamant Building Bd A. Reyers 80 1030 Brussels, Belgium
Tel: +32 (0)2 238 97 11
essenscia is a multisectoral umbrella organisation that represents the numerous sectors of activities in the field of chemicals and the life sciences. It includes nearly 800 companies representing more than 95% of the overall turnover in the sector.
The structure of essenscia is modelled on the reality of the Belgian institutions, with federal, regional and community areas of competence. essenscia bruxelles, essenscia vlaanderen and essenscia wallonie, the three regional sections of essenscia, act as spokesmen for companies to the Brussels, Flemish and Walloon authorities on regional and community matters. essenscia is made up of multidisciplinary skills centres which also deal with the main issues, irrespective of the level of power. The 17 professional sections of essenscia represent and promote interests specific to their sector of activities.
essenscia represents and defends the sector’s interests at a European level through active involvement in Cefic (the European Council of Chemical Manufacturers’ Federations) and the FEB (Federation of Belgian Companies).
Janssen in Belgium was founded in 1953 by Dr Paul Janssen, with only one thing in mind: saving people’s lives through the development of better medicines. In 1961, the company…
Professor Sylvie Rottey, president of the Belgian Society of Medical Oncology (BSMO) outlines the state of cancer care in Belgium, the country’s positioning in clinical trials for medical oncology, and…
Erik Present is president of Healixia, a newly formed association for medical professionals in Belgium. Present introduces the mission and purpose of Healixia, the work it is currently undertaking in…
Sabena Solomon, general manager of GSK Benelux, speaks about her first impressions of the Belgium market, having come from GSK Finland, and her initial priorities for leading the affiliate. Solomon…
Karel Van De Sompel, country manager of Pfizer in Belgium and Luxembourg and chairman of Pharma.be, highlights the key changes he sees in today’s pharma market which revolve around the…
Professor Stéphane De Wit, head of the Department of Infectious Diseases at St Pierre University Hospital outlines Belgium’s approach to tackling HIV treatment, how academia-industry collaboration is progressing in the…
In 2020 PharmaBoardroom sat down with several key stakeholders in Belgian pharma to discuss company strategy, the Belgian healthcare landscape at large, and the country’s role within the wider European…
Francis Arickx, country coordinator of Belgium for the Beneluxa Initiative, introduces the project and its mission to help shape a unified healthcare policy approach between its member countries through activities…
Ian Wilders of Spain-headquartered micro-immunotherapy specialist Labo’Life discusses the strategic importance of Belgium to the company as the country in which micro-immunotherapy was discovered and where regulation conducive to the…
Luc Van Gorp of the Christian Mutuality Health Insurance Fund, Belgium’s largest health insurance fund, explains the organisation’s role within the Belgian healthcare system, how increased consolidation in recent years…
Dirk Reyn of Flanders.bio highlights what the Flanders region has to offer the life sciences and biotech industries in terms of research infrastructure, funding opportunities, and inter-industry collaboration. In…
Anne-Laure Dreno, country president of AstraZeneca in Belgium, elaborates on the significant position Belgium and the local affiliate have for the group as a frontrunner in innovative areas such as…
See our Cookie Privacy Policy Here
